That's a great board.
Your fellow posters Gary, djjohnson, yourself, and many more, are a worth while read with good solid information, A+, imo.
For myself, the settlement with DSE back a while ago, was a key pivotal point to continue to hold ESPR. That event says to me that mgmt. is not narrow visioned and both parties realized that they should not delay progress of a potential blockbuster therapy.
I still see DS as the most logical partner / buyer
On the other hand, with all the absolute positive news - FDA label and on and on, it's hard to believe we are still in the $2 zone. In this area, mgmt. has failed to date, whether we have to endure this for the better some day remains to be seen.
I can understand the frustrations of longer term holders with current mgmt.
Market Data 
Markets 
AI
